$38.28
0.73% today
NYSE, Sep 11, 03:54 pm CET
ISIN
US6031701013
Symbol
MLYS

Mineralys Therapeutics Stock price

$38.56
+25.37 192.34% 1M
+23.60 157.75% 6M
+26.25 213.24% YTD
+26.55 221.07% 1Y
+20.12 109.11% 3Y
+20.12 109.11% 5Y
+20.12 109.11% 10Y
+20.12 109.11% 20Y
NYSE, Closing price Wed, Sep 10 2025
+0.06 0.16%
ISIN
US6031701013
Symbol
MLYS
Industry

Key metrics

Basic
Market capitalization
$2.9b
Enterprise Value
$2.6b
Net debt
positive
Cash
$324.9m
Shares outstanding
65.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.4
Financial Health
Equity Ratio
92.9%
Return on Equity
-93.0%
ROCE
-64.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-203.0m | $-204.7m
EBIT
$-203.1m | $-193.1m
Net Income
$-190.8m | $-180.0m
Free Cash Flow
$-193.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-51.2% | -6.4%
EBIT
-51.2% | -0.4%
Net Income
-59.3% | -1.2%
Free Cash Flow
-99.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.9
FCF per Share
$-2.9
Short interest
14.7%
Employees
51
Rev per Employee
$0.0
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Mineralys Therapeutics forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Mineralys Therapeutics forecast:

Buy
87%
Hold
13%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
55% 55%
-
- Research and Development Expense 175 175
50% 50%
-
-203 -203
51% 51%
-
- Depreciation and Amortization 0.05 0.05
150% 150%
-
EBIT (Operating Income) EBIT -203 -203
51% 51%
-
Net Profit -191 -191
59% 59%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Positive
The Motley Fool
4 days ago
Investors in search of stocks that can produce dramatic gains in a short time frame will want to turn their heads toward the healthcare sector. A handful of stocks in the space more than doubled in price recently.
Neutral
GlobeNewsWire
6 days ago
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~
Neutral
GlobeNewsWire
7 days ago
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of its previously announced u...
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 51
Founded 2019
Website mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today